43 results about "Hepatitis B Virus Antigen" patented technology

The invention involves novel drug use of six-rowed chrysanthemum plant extracts which is used to treating herpes simplex virus (type 1 and / or type 2) and various disease caused by hepatitis B virus infection. The six-rowed chrysanthemum plant extracts is prepared by six-rowed chrysanthemum plant fresh or dry goods through the refining of alcohol-water extraction, column chromatography, alcohol solvent elution, the amount of caffeoyl guinic acid chemical compound is below 30%. The six-rowed chrysanthemum plant extracts prepared in the invention has significant function of inhibiting herpes simplex virus with type 1 (HSV-1), herpes simplex virus type 2 (HSV-2) and hepatitis B virus (HBV) replication, and can reduce effectiveness of HBV e antigen (HBeAg) in the HepG 2.2.15 cell lines, it can be used for treatment various disease caused by said correlate virus infection.

Pharmaceutical compositions of the invention comprise triazolopyrimidines useful for the treatment of hepatitis virus in a patient.

The invention provides a specific sgRNA combined with an immunogene to inhibit HBV replication, an expression vector thereof, and an application of the specific sgRNA and the expression vector. The sgRNA sequences of a human hepatitis B virogene suitable for CRISPR-Cas9 targeting editing and a PD-1 gene are designed, the plasmid vector of the sgRNA inhibiting HBV and PD-1 genes is constructed, and the plasmid vector and a nuclease gene expression vector are transferred to HBV transgenic mice, and can obviously inhibit HBV DNA replication. The gene expression vector prepared in the invention has the advantages of simple method steps, good sgRNA targeting property, and high CRISPR-Cas9 knockout efficiency. The sgRNAs specifically targeting the HBV and PD-1 genes can accurately splice the HBV and PD-1 genes, inhibit in vivo hepatitis B virus replication, and reduce the hepatitis B virus antigen expression.

Pharmaceutical compositions of the invention comprise triazolopyrimidines useful for the treatment of hepatitis virus in a patient.

Peptides are used to define epitopes that stimulate HLA-restricted cytotoxic T lymphocyte activity against hepatitis B virus antigens. The peptides are derived from regions of HBV polymerase, and are particularly useful in treating or preventing HBV infection, including methods for stimulating the immune response of chronically infected individuals to respond to HBV antigens.

This invention relates to hepatitis B virus chemical light qualitative and quantitative test method, which tests hepatitis B surface antigen through its HBsAg and tests hepatitis B surface antibody through antibody HBs chemical test agent case and tests hepatitis B virus antigen through hepatitis antigen HBeAg test agent case and tests hepatitis virus e antibody through virus e antibody chemical property and tests hepatitis virus core antibody through virus core antibody chemical property.

The invention provides a multivalent immunogenic composition, which includes an inactivated hepatitis A antigen and an inactivated poliovirus. The composition also can further include over one or two of a purified pertussis antigen, diphtheria toxoid, tetanus toxoid, filamentous hemagglutinin, Haemophilus influenzae type b polysaccharide, Neisseria meningitidis capsular polysaccharide, a hepatitis B virus antigen, enterovirus 71 and a coxsackievirus A16 antigen, and a physiologically acceptable carrier. The composition involved in the invention is employed to immunize the inoculated population in the form of a bivalent vaccine or more combined vaccines. Without reducing the immune effects of each immunizing antigen, the inoculation number of times can be reduced at the same time, and the time and human resources can also be saved.

[PROBLEMS] To provide a probe useful in the detection of HBV or HBs antigen by which an escape mutant of hepatitis B virus (HBV) possibly occurring in a specimen can be detected; and a method of using the same.[MEANS FOR SOLVING PROBLEMS]A probe capable of recognizing an epitope located on a peptide comprising the amino acid sequence of SEQ ID NO:1; and a method of detecting hepatitis B virus or hepatitis B virus s antigen by using this probe.

Peptides are used to define epitopes that stimulate HLA-restricted cytotoxic T lymphocyte activity against hepatitis B virus antigens. The peptides are derived from regions of HBV polymerase, and are particularly useful in treating or preventing HBV infection, including methods for stimulating the immune response of chronically infected individuals to respond to HBV antigens.

A pharmaceutical composition comprising an effective amount of a compound of formulas (I-III) and a pharmaceutically acceptable carrier. Methods for treating a hepatitis virus in a patient comprising administering an effective amount of the compound of formulas (I-III) are also presented.

The invention discloses a compound of a hepatitis B virus antigen and lewis oligosaccharide and a preparation method and application thereof. The compound is prepared mainly through combination of a core hepatitis B virus antigen and lewis oligosaccharides-x. The preparation method comprises the following steps: preparing a conjugate of the core hepatitis B virus antigen and streptavidin, and combining the conjugate with (lewis oligosaccharides-x)-sodium polyacrylate-biotin through high affinity of the streptavidin and the biotin, thereby preparing the compound of the hepatitis B virus antigen and the lewis oligosaccharide. The compound enhances the capability of recognition of a immune system to the hepatitis B virus due to the active targeting of dendritic cells through the high affinity of the lewis oligosaccharides-x and DC-SIGN, can activate specific CTL responses and induce strong anti-viral immunity, and can be applied in the preparation of vaccines for treatment of the hepatitis B.

The invention provides an anti-HBV medicine combination which has more remarkable treatment effect and safety and no toxic and side effect and can evidently increase the negative conversion ratio of HBSAg. The invention takes HepG2.2.15 as a target cell and adds lamivudinevir, protocatechuic acid and the compatibility preparation of lamivudinevir and protocatechuic acid with a proper concentration to cell culturing medium. The cell is cultured by a regular method and HBsAg and HBeAg secreted by the cell is detected by ELISA method, HBV DNA content is measured by fluorescent quantitation PCR, HBV resistance effect of the drug is judged by depression rate calculation method to determine the medical treatment effect on HBV and the preparation proportion of medicine combination. The proportion of lamivudinevir to protocatechuic acid is between 1 to 50 and 1 to 100 (mass ratio) and generally the dosage of lamivudinevir is 0.05-5Mug and the protocatechuic acid is 5-500 Mug. The medicine combination can evidently improve the depression effect of the lamivudinevir on Hepatitis B antigen and reduce the toxic and side effect of the lamivudinevir when being used separately.

The invention discloses a recombinant chimeric protein carrying a hepatitis B virus epitope and the preparation thereof, particularly a recombinant chimeric protein respectively carrying a hepatitis B virus S82, C19, S125, S2[8], S1[93] or C117 epitope, and a recombinant chimeric protein simultaneously carrying hepatitis B virus S82, C19, S125, S2[8], S1[93] and C117 epitopes, and through the immunology WesternBlot detection, each recombinant protein not only has the antigen reactivity and the immunogenicity of a VP6F protein, but also has the antigen reactivity and the immunogenicity of the HBV (hepatitis B virus) epitope, does not have infectivity and the side effects of virulence atavism, the intussusception and the like, and has important value for developing new generation RV (Rota Virus) / HBV recombinant chimeric vaccine and reagent.

The invention relates to a human anti-hepatitis B virus surface antibody as well as a preparation method and application thereof. A specific hepatitis B antibody with relatively high affinity activity on hepatitis B virus antigens can be obtained by virtue of antigen-antibody binding activity screening, wherein an amino acid sequence of a light chain variable region of the antibody is shown in SEQ ID No. 1 or SEQ ID No. 2, and an amino acid sequence of a heavy chain variable region of the antibody is shown in SEQ ID No. 3 or SEQ ID No. 4. According to the human anti-hepatitis B virus surface antibody disclosed by the invention, antibody mutation hot spots are analyzed by virtue of a protein molecule modeling technology and are subjected to saturation mutation by taking an amino acid as a unit so as to construct a mutant library and perform biological verification, and thus optimization of the antibody can be achieved. The human anti-hepatitis B virus surface antibody disclosed by the invention can be used for laying a foundation for preventing hepatitis B virus infection and performing treatment research at the same time, so that the human anti-hepatitis B virus surface antibody can be applied to the prevention and treatment of liver diseases caused by hepatitis B virus infection clinically.

Disclosed is a recombinant plasmid for expressing hepatitis B viral antigens in vivo, comprising an adeno-associated virus (AVV) vector and a replication-competent hepatitis B virus genome fragment. Mice hydrodynamically injected with the recombinant plasmid of the present invention show persistent expression of hepatitis B viral antigens for more than 6 months in the hepatocytes, thus a immuno-competent mouse model for persistent expression of hepatitis B antigens and also for human chronic hepatitis B virus infection is established, which can be applied in evaluation and elucidation of mechanism of chronic hepatitis and anti-viral drug discovery research.

The invention discloses a group of thymus dependent lymphocyte antigen epitope peptide sequences of a hepatitis B virus antigen. Molecule-limited antigen peptides, such as HLA-A*0101, A*0301, A*3001, A*3101, A*3201, A*3303, and A*6801 can be specifically combined with cytotoxicity thymus dependent lymphocytes, and then the activation, proliferation and differentiation of the cytotoxicity thymus dependent lymphocytes are promoted, so as to perform the immunity effect action of resisting the hepatitis B virus. The antigen peptides can be used for preparing vaccines for treating and preventing the infection of hepatitis B virus, and also can be used for preparing detection reagents for detecting the specific cytotoxicity thymus dependent lymphocytes of the hepatitis B virus, and the potential application value is realized in the prevention, treatment and diagnosis of the hepatitis B virus.

The invention relates to preparation method for an immunological hepatitis animal model induced by hepatitis B virus whole genome transfected mouse hepatocytes, especially to an immunological inducer containing hepatocyte autoantigens and hepatitis B virus antigens and a simple operation procedure, generation of an immunological hepatitis disease model more similar to human diseases and application of the model in hepatitis pathogenesis study and anti-hepatitis drug evaluation.

The present invention relates to the field of therapeutic immunization, specifically with the use of a novel hepatitis B virus (HBV) antigen formulation for cell stimulation. The formulation is formed by HBV surface antigen (HBsAg) and nucleocapsid antigen (HBcAg) precipitates in suspension. The formulation contains said antigens as precipitates in suspension as particles with sizes less than 500 nm and greater than 500 nm, in a mixture in which the proportion between the particles of the sizes mentioned is between 50% - 50% and 80% - 20%, respectively. The selection of a range of particle sizes allows the levels of stimulation of various cell types to be maximized. In addition, a description is given of a method for cell stimulation using said formulation and the subsequent passive immunization of patients with chronic hepatitis B, based on the maximum in vivo or in vitro stimulation of heterologous or autologous cells (dendritic cells, B cells and macrophages). The cells stimulated with this formulation are transferred to patients with a chronic HBV infection.

This disclosure provides a multimeric hepatitis B virus (HBV) protein binding molecule, e.g., a dimeric IgA or a pentameric or hexameric IgM binding molecule, comprising at least two bivalent bindingunits, or variants or fragments thereof, each comprising at least two antibody heavy chain constant regions or fragments thereof, wherein each heavy chain constant region or fragment thereof is associated with an HBV antigen binding domain. The disclosure also provides compositions comprising the multimeric binding molecules, polynucleotides encoding the multimeric binding molecules, and methods to make and use the multimeric binding molecules.

The invention discloses application of rotundic acid in preparation of an anti-hepatitis B virus (HBV) medicine for the first time, and especially discloses application of the rotundic acid in preparation of medicines for inhibiting secretion of HBV surface antigen or HBV E antigen. In-vitro HepG22.2.15 cell pharmacological experiments prove that rotundic acid has excellent anti-HBV effect, and has the advantages of relatively low effective concentration and relatively small cytotoxicity. The rotundic acid has an effect for inhibiting HBsAg and HBeAg, has the inhibition rates for HBsAg and HBeAg respectively being 39 / 5 percent and 40.2 percent at 100mu g / ml, and has the inhibition effect for HBV superior to that of positive control lamivudine, oleanolic acid and ovate leaf holly bark medicinal material extract.

The invention discloses an antigen presentation signal group of hepatitis B virus (HBV) antigen peptide combined with liver cancer cell antigen information and its application. The signal group consists of HBV core antigen 18-27 peptide segment, HBV pre-S2 antigen 44-53 peptide segment and The composition of human liver cancer cell line HepG2 lysate, the mass ratio of HBV core antigen 18-27 peptide, HBV pre-S2 antigen 44-53 peptide and human liver cancer cell line HepG2 lysate is 0.5~1:0.5~1:1 ~2. The DC cells induced by this signal group become a DC vaccine carrying multiple specific HBV-associated liver cancer antigen signals, which can activate the proliferation and function of tumor-specific T cells, thereby strengthening its role in fighting HBV liver cancer.

The invention discloses application of a substance for inhibiting LSECtin in preparing a medicine for treating and / or preventing viral hepatitis B. The invention provides application of the substance for inhibiting LSECtin in preparing a product with the following purposes: (a) treating and / or preventing viral hepatitis B; (b) promoting elimination of hepatitis B virus antigen in an infected person of hepatitis B virus; (c) treating and / or preventing infection of HBV (Hepatitis B Virus); (d) inhibiting duplication of hepatitis b viral hepatitis virus; (e) promoting increase of proportion of CD25 positive cells in liver lymphocyte; (f) promoting decrease of CD62 positive cells in liver lymphocyte; (g) promoting decrease of proportion of CD127 positive cells in liver lymphocyte; (h) promoting increase of proportion of cells which secrete interferon-gamma in liver lymphocyte. The substance disclosed by the invention has huge social meaning and economic value.

The invention relates to a vaccine for treating chronic hepatitis B and a preparation method and application thereof. The vaccine is prepared from a hepatitis B virus antigen and a compound adjuvant containing a molecular adjuvant. The vaccine can not only induce strong antibody response, but also induce strong cellular immune response. A carrier of the compound adjuvant used can deliver the antigen to a lymphatic system very effectively. The molecular adjuvant can activate T cell subsets and effectively increase the level and the persistence of an antibody and cellular immune response. The antibody against the hepatitis B virus antigen produced after immunization can eliminate the virus and the antigen in the blood circulation. The vaccine can quickly reduce or even eliminate the antigenof the virus in the blood, eliminate the hepatitis B virus in the liver cells, and prevent the patient from carrying the hepatitis B virus.

Disclosed herein is a multimerized hepatitis B virus (HBV) protein binding molecule, such as a bivalent IgA or pentameric or hexameric IgM binding molecule, comprising at least two bivalent binding units, or variants or Fragments, each comprising at least two antibody heavy chain constant regions or fragments thereof, wherein each heavy chain constant region or fragment thereof is associated with an HBV antigen binding domain. Also disclosed herein are compositions comprising multimerized binding molecules, polynucleotides encoding multimerized binding molecules, and methods of making and using multimerized binding molecules.

The present invention discloses an antigen presenting signal group combining hepatitis B virus (HBV) antigen peptides and liver cancer cell antigen information, and applications, wherein the signal group comprises a HBV core antigen 18-27 peptide fragment, a HBV PreS2 antigen 44-53 peptide fragment and a human liver cancer cell line HepG2 lysate according to a mass ratio of 0.5-1:0.5-1:1-2. According to the present invention, DC cells induced by the signal group become the DC vaccine carrying the antigen signals of multi-specific hepatitis B virus-associated liver cancers, and can activate the proliferation and the function of tumor-specific T cells so as to enhance the anti-hepatitis B liver cancer effect.